Proscia, a pathology AI company, announced the launch of Proscia Aperture, a new precision medicine solution designed to address a critical challenge in healthcare: identifying eligible patients for clinical trials and next-generation therapies. , a pathology AI company, announced the launch of Proscia Aperture, a new precision medicine solution designed to address a critical challenge in healthcare: identifying eligible patients for clinical trials and next-generation therapies.
This groundbreaking platform automatically identifies potential candidates at the very moment of diagnosis by leveraging AI to transform routine pathology data into real-time insights.
By doing so, Aperture provides biopharmaceutical companies with the critical intelligence needed to accelerate the development of new treatments and, ultimately, expand access to these life-saving therapies for millions of patients.
Currently, less than one in ten cancer patients enroll in clinical trials, and many miss out on potentially life-saving therapies. Diagnostic laboratories are in a unique position to close this gap because they sit at the intersection of pathology, molecular, and clinical insights. With the shift to digital pathology, each tissue image contains a rich, detailed profile of a disease. However, this valuable data has largely been disconnected from the drug development process. Proscia Aperture solves this by tapping into a global network of laboratories that are expected to deliver over 8 million pathology diagnoses this year through the company's Concentriq® platform. The solution’s AI analyzes tissue images, AI-derived biomarkers, molecular results, and clinical records to generate evidence for a variety of applications, including regulatory submissions, companion diagnostic development, and label expansions. The platform also surfaces eligible candidates for clinical trials.
Aperture enhances the scale and diversity of its intelligence by utilizing Proscia’s real-world data repository, which contains more than 12 million tissue images along with clinical and genomic records. Patient privacy is protected through strict de-identification and governance. The solution not only benefits biopharmaceutical companies by accelerating drug development but also helps diagnostic laboratories. For participating academic medical centers, healthcare systems, and reference laboratories, Aperture transforms pathology from a diagnostic function into a strategic revenue driver. It allows laboratories to broaden their service offerings, differentiate themselves from competitors, and establish themselves as essential research-driving centers, which is crucial in the face of shrinking margins and workforce shortages. According to Proscia CEO David West, Aperture demonstrates that pathology is no longer the end of the diagnostic journey but the start of what's next for patients, uniting research and care to make the future of pathology a reality.